期刊文献+

166株铜绿假单胞菌的分布及耐药性分析 被引量:7

Distribution and drug resistance of Pseudomonas aeruginosa:analysis of 166 strains
暂未订购
导出
摘要 目的了解2006年1月至2008年12月本院铜绿假单胞菌的分布及对不同类型抗菌药物的耐药情况,以指导临床合理用药。方法收集临床送检分离的铜绿假单胞菌进行耐药性监测,采用纸片扩散法(K-B法)进行监测,结果根据美国临床实验室标准化委员会(NCCLS)相关文件判断。结果铜绿假单胞菌对氨苄西林、复方新诺明、头孢噻肟的耐药率均大于40%,对亚胺培南的耐药率最低,约为5%。结论铜绿假单胞菌仍是医院病原菌感染的主要致病菌之一,加强耐药性监测,合理应用抗菌药物是十分重要的。 Objective To investigate the change in antimicrobial resistance to Pseudomonas aeruginosa in our haspital from Jan,2006 to Dee,2008 and to direct the using of drugs reasonably. Methods The clinically isolated P. aeruginosa strains were collected, surveillance of drug resistance by paper diffusing method, the results were evaluated according to the relevant documents of NCCLS of USA. Results The resistant rates of P. aeruginosa to AMP,SMI, and CTX were higher than 40 %. The resistant rate to IMP was the lowest (about 50% or so ). Conclusion P. aeruginosa is still a major pathogenic bacterium in our hospital. It is very important to select antibiatics correctly according to the results of susceptibility tests.
出处 《检验医学与临床》 CAS 2010年第3期220-220,223,共2页 Laboratory Medicine and Clinic
关键词 铜绿假单胞菌 标本分布 药物耐药性监测 pseudomonas aeraginosa distribution of samples surveillance of drug resistance
  • 相关文献

参考文献6

二级参考文献21

  • 1金美娟,李秀红,邢旺兴.236株铜绿假单胞菌感染的临床分析[J].中华医院感染学杂志,2005,15(3):348-350. 被引量:45
  • 2梁勇,陈裔.临床分离铜绿假单胞菌体外耐药的动态观察[J].中华医院感染学杂志,2005,15(5):594-595. 被引量:48
  • 3钱小毛,赵仲农,王亚玲.绍兴地区铜绿假单胞菌亚胺培南耐药机制研究[J].中华医院感染学杂志,2005,15(7):815-818. 被引量:36
  • 4[2]NCCLS.Performance standards for antimicrobial disk susceptibility tests: Approved Standard[S].Eighth Edition,M2-A8.2003.23(1): 100.
  • 5[5]Jing JY,Po Rhsueh.β-Lactamases in clinical Pseudomonas isolates[J].Antimicrob Agents Chemother,2001,45(8): 2224-2228.
  • 6Livermore DM. Multiple mechanism of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare[J].Antimicrob Resist, 2002, 34(3): 634-640.
  • 7Arakawa Y, Shibata N, Shibayama K, et al. Convenient test for screening metallo-β-lactamase-producing Gram-negative bacteria by using thiol compounds[J]. J Clin Microbiol,2000,38(1) :40-43.
  • 8Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors formor tality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome[J]. Clin Infect Dis, 2003, 37(3); 745-751.
  • 9Paramythiotou E,Lucet JC,Timsit JF,et al.Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units:role of antibiotics with antipseudomonal activity[J].Clin Infect Dis,2004,38(3):670-677.
  • 10Aloush V,Navon-Venezia S,Seigman-Igra Y,et al.Multidrug-resistant Pseudomonas aeruginosa:risk factors and clinical impact[J].Antimicrob Agents Chemother,2006,50(1):43-48.

共引文献252

同被引文献50

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部